Heparin Market to Reach US$14.3 by 2023, Rising Incidence of Coagulation Disorders to act as Growth Driver

Global Heparin Market: Key Trends

The prevalence of coagulation disorders such as venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) has remarkably increased in both Europe and North America. Since heparin is one of the foremost clinical anticoagulants, the rising incidence of coagulation disorders will in turn fuel demand for heparin products, finds Transparency Market Research (TMR). Currently, heparin manufacturers are focusing on the development of generic versions of heparin to gain a competitive advantage in the market.

Read Report Description of Heparin Market: http://www.transparencymarketresearch.com/heparin-market.html

Naturally derived heparin products can cause severe side-effects in the event of an overdose. Scientists are therefore developing synthetic heparin products, which are both safer and cheaper. While declining imports from China will emerge as a major growth bottleneck, with the advent of biosimilars, heparin manufacturers will witness improved scope for expanding their product portfolio.

According to TMR, the global heparin market stood at US$8.2 bn in 2014. Exhibiting a CAGR of 6.3% between 2015 and 2023, the market is expected to reach US$14.3 bn by the end of 2023.

North America Reports Highest Demand for Heparin Due to Rising Prevalence of Coagulation Disorders

Regionally, North America emerged as the largest market for heparin products in 2014. As per the Centers of Disease Control and Prevention (CDC), nearly 900,000 people in the U.S. are affected by DVT and PE every year. Moreover, due to the sophisticated healthcare infrastructure the country boasts, the U.S. is visited by an increasing number of medical tourists annually. The overall number of surgical procedures conducted in the country is thus comparatively higher. This fuels demand for heparin products from North America. TMR projects the North America heparin market to rise at a CAGR of 6.3% between 2014 and 2023.

Europe emerged as the second largest market for heparin products in the same year. The U.K., Germany, and France are the most lucrative markets for heparin in the region. However, as per Transparency Market Research, the heparin market in Asia Pacific is expected to exhibit the fastest growth during the forecast period. The incidence of VTE has nearly doubled in India in the last decade.

Despite economic growth witnessed across the emerging nations of Asia Pacific, the unavailability of appropriate diagnostic centers and lack of awareness are leading to a lesser number of cases of DVT being reported. Nevertheless, GDP growth, increasing spending in healthcare infrastructure, and rising geriatric population are expected to fuel demand for heparin from Asia Pacific in the forthcoming years.

Low Molecular Weight Heparins Emerge as Standard Choice of Drug Care for Arterial and Venous Thrombosis

The most commonly used heparin products include ultra-low molecular weight heparin (ULMWH), low molecular weight heparin (LMWH), and unfractionated heparin. Although the demand for LMWHs is higher, the choice of heparin depends on the disease and patient’s condition. Low molecular weight heparins offer proven benefits over unfractionated heparins, due to which the demand for the former is rising at a higher pace.

Currently, LMWHs are considered the standard choice of care drugs for the treatment of arterial and venous thrombosis. This category of heparins also exhibits comparatively lesser side-effects, which is expected to bolster their sales in the forthcoming years. According to TMR, the LMWHs segment is expected to reach US$12.3 bn by the end of 2023. Demand from the ULMWHs segment is expected increase due to the rising use of these anticoagulants as an alternative to unfractionated heparin in dialysis.

Request for the Sample Report:: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=803

Some of the leading players operating in the market are Fresenius Kabi AG, Dr. Reddy's Laboratories Ltd., Mylan N.V., LEO Pharma A/S, Pfizer, Inc., Syntex S.A., Sanofi S.A., and Teva Pharmaceutical Industries Ltd.

About TMR

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.